Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells
- PMID: 28225830
- PMCID: PMC5338860
- DOI: 10.1371/journal.ppat.1006230
Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells
Abstract
The fate of HIV-infected cells after reversal of proviral latency is not well characterized. Simonetti, et al. recently showed that CD4+ T-cells containing intact proviruses can clonally expand in vivo and produce low-level infectious viremia. We hypothesized that reversal of HIV latency by activation of CD4+ T-cells can lead to the expansion of a subset of virus-producing cells rather than their elimination. We established an ex vivo cell culture system involving stimulation of CD4+ T-cells from donors on suppressive antiretroviral therapy (ART) with PMA/ionomycin (day 1-7), followed by rest (day 7-21), and then repeat stimulation (day 21-28), always in the presence of high concentrations of raltegravir and efavirenz to effectively block new cycles of viral replication. HIV DNA and virion RNA in the supernatant were quantified by qPCR. Single genome sequencing (SGS) of p6-PR-RT was performed to genetically characterize proviruses and virion-associated genomic RNA. The replication-competence of the virions produced was determined by the viral outgrowth assay (VOA) and SGS of co-culture supernatants from multiple time points. Experiments were performed with purified CD4+ T-cells from five consecutively recruited donors who had been on suppressive ART for > 2 years. In all experiments, HIV RNA levels in supernatant increased following initial stimulation, decreased or remained stable during the rest period, and increased again with repeat stimulation. HIV DNA levels did not show a consistent pattern of change. SGS of proviruses revealed diverse outcomes of infected cell populations, ranging from their apparent elimination to persistence and expansion. Importantly, a subset of infected cells expanded and produced infectious virus continuously after stimulation. These findings underscore the complexity of eliminating reservoirs of HIV-infected cells and highlight the need for new strategies to kill HIV-infected cells before they can proliferate.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: JWM is a consultant for Gilead Sciences and a shareholder of Cocrystal Pharma, Inc. WS and BL are employees of Leidos Biomedical Research, Inc.
Figures






Similar articles
-
Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.J Virol. 2019 May 15;93(11):e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1. J Virol. 2019. PMID: 30918072 Free PMC article.
-
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.Proc Natl Acad Sci U S A. 2014 May 13;111(19):7078-83. doi: 10.1073/pnas.1402873111. Epub 2014 Mar 31. Proc Natl Acad Sci U S A. 2014. PMID: 24706775 Free PMC article.
-
HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo.J Virol. 2015 Nov 11;90(3):1673-6. doi: 10.1128/JVI.02520-15. Print 2016 Feb 1. J Virol. 2015. PMID: 26559835 Free PMC article.
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Single-molecule techniques to quantify and genetically characterise persistent HIV.Retrovirology. 2018 Jan 9;15(1):3. doi: 10.1186/s12977-017-0386-x. Retrovirology. 2018. PMID: 29316955 Free PMC article. Review.
Cited by
-
Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy.J Cell Mol Med. 2022 Feb;26(3):940-944. doi: 10.1111/jcmm.16885. Epub 2022 Jan 11. J Cell Mol Med. 2022. PMID: 35014164 Free PMC article.
-
Combination Immune Checkpoint Blockade to Reverse HIV Latency.J Immunol. 2020 Mar 1;204(5):1242-1254. doi: 10.4049/jimmunol.1901191. Epub 2020 Jan 27. J Immunol. 2020. PMID: 31988180 Free PMC article.
-
Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.PLoS Pathog. 2017 Mar 22;13(3):e1006283. doi: 10.1371/journal.ppat.1006283. eCollection 2017 Mar. PLoS Pathog. 2017. PMID: 28328934 Free PMC article.
-
HIV evolution and diversity in ART-treated patients.Retrovirology. 2018 Jan 30;15(1):14. doi: 10.1186/s12977-018-0395-4. Retrovirology. 2018. PMID: 29378595 Free PMC article. Review.
-
Latency Reversing Agents and the Road to an HIV Cure.Pathogens. 2025 Feb 27;14(3):232. doi: 10.3390/pathogens14030232. Pathogens. 2025. PMID: 40137717 Free PMC article. Review.
References
-
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300. - PubMed
-
- Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials